| Could thyroid dysfunction influence outcome in sunitinib-treated metastatic ... - UroToday |
|
|
UroToday Sunitinib is a standard of care for metastatic renal cell carcinoma (mRCC). Hypothyroidism is frequently observed under sunitinib therapy. This study was conducted to prospectively determine the correlation between thyroid function and progression-free |